SHINE Study: Illuminating the Promise of Nusinersen in SMA Treatment
This study explores the background and rationale behind utilizing nusinersen for the treatment of Spinal Muscular Atrophy (SMA), shedding light on the critical need for the SHINE study. Delving into the characteristics of the patient population involved, the research aims to deepen our understanding of the therapeutic potential of nusinersen in addressing SMA, a debilitating genetic disorder.
In the "Between the Lines" program, Jim Kenney and Dr. Thomas Crawford discuss the transformative developments in treating spinal muscular atrophy (SMA) through long-term treatment with nusinersen, highlighted by the SHINE and NURTURE studies. Dr. Crawford reflects on the significant progress made over 25 years, turning SMA from a seemingly incurable disease with high mortality rates into a success story in molecular medicine.
Nusinersen, an antisense oligonucleotide (ASO), is a DNA-like molecule introduced intrathecally to modify the splicing of a backup gene in the spinal column, leading to the production of a functional protein. This breakthrough treatment has shifted SMA from a state of minimal protein expression to normal levels, setting a precedent for addressing various genetic diseases.
The conversation delves into the rationale behind the CHERISH and SHINE studies, exploring the challenges of using a novel therapy like nusinersen. Dr. Crawford emphasizes the importance of determining the right dose, frequency, patient selection, and outcome measures. The SHINE study, a compilation of various studies, was designed to harmonize and understand the long-term effects of treating SMA. Unexpectedly successful, the study had to end early due to its remarkable outcomes, leading to its publication in the New England Journal of Medicine.
The SHINE Study, transitioning patients to a single dose of nusinersen, aimed to assess safety and functional outcomes over time. Dr. Crawford explains the study's unique approach, including the blending of patients from previous studies, providing valuable insights into the impact of nusinersen on SMA patients over the long haul. The program showcases the journey from despair to hope in treating SMA and the potential implications for addressing other genetic diseases in the future.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
